Epigenetic and phenotypic signatures of T-cell response to blinatumomab in pediatric relapsed and refractory B-ALL. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback